These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14870891)

  • 1. Adoptive immunotherapy as consolidation of remission in pediatric AML relapsing post-transplant.
    Vettenranta K; Hovi L; Saarinen-Pihkala UM
    Pediatr Transplant; 2003 Dec; 7(6):446-9. PubMed ID: 14870891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
    Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.
    Yan CH; Wang Y; Wang JZ; Chen YH; Chen Y; Wang FR; Sun YQ; Mo XD; Han W; Chen H; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2016 Sep; 9(1):87. PubMed ID: 27629395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
    Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
    Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.
    Vandenberghe P; Verhoef GE; Emonds MP; Demuynck H; Zachée P; De Wolf-Peeters C; Decorte R; Cassiman JJ; Boogaerts MA
    Leukemia; 1997 Oct; 11(10):1775-8. PubMed ID: 9324300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
    Gergis U; Frenet EM; Shore T; Mayer S; Phillips A; Hsu JM; Roboz G; Ritchie E; Scandura J; Lee S; Desai P; Samuel M; Ball J; Blanco A; Romeo C; Albano MS; Dobrila L; Scaradavou A; van Besien K
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):466-473. PubMed ID: 30414955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
    Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
    Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
    Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
    Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
    Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-CSF-mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    J Hematother; 1998 Oct; 7(5):449-56. PubMed ID: 9829319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsing AML following hematopoietic stem cell transplantation.
    Atlas MP; Lipton JM
    Pediatr Transplant; 2003 Dec; 7(6):419-21. PubMed ID: 14870887
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies.
    Champlin R; Gale RP
    Semin Hematol; 1987 Jan; 24(1):55-67. PubMed ID: 3547673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.